The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
Open accessAbstract
A ROS-responsive hydrogel scaffold controls release of gemcitabine and immune checkpoint inhibitor for enhanced antitumor activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Reactive oxygen species in cancer
Liou, G.-Y., & Storz, P. (2010) · Free Radical Research · doi:10.3109/10715761003667554 · Cited by 3,382
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Chen, Q., Wang, C., Zhang, X., Chen, G., Hu, Q., Li, H., Wang, J., Wen, D., Zhang, Y., Lu, Y., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0319-4 · Cited by 1,010
Self-citationROS-scavenging hydrogel to promote healing of bacteria infected diabetic wounds
Zhao, H., Huang, J., Li, Y., Lv, X., Zhou, H., Wang, H., Xu, Y., Wang, C., Wang, J., & Liu, Z. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120286 · Cited by 841
Self-citationTurning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y.-T., & Sun, Z.-J. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 827
Hydrogels and Their Applications in Targeted Drug Delivery
Narayanaswamy, R., & Torchilin, V. P. (2019) · Molecules · doi:10.3390/molecules24030603 · Cited by 664
Metadata
- Authors
- Wang, C., Wang, J., Zhang, X., Yu, S., Wen, D., Hu, Q., Ye, Y., Bomba, H., Hu, X., Liu, Z., Dotti, G., & Gu, Z.
- Venue
- Science Translational Medicine
- Published
- 2018-02-21
- Volume
- 10
- Issue
- 429
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2788206402
- Cited by
- 591
- References
- 60
- FWCI
- 24.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. https://app.cochat.ai/papers/10.1126/scitranslmed.aan3682
- The paper
- Wang, C., Wang, J., Zhang, X., Yu, S., Wen, D., Hu, Q., Ye, Y., Bomba, H., Hu, X., Liu, Z., Dotti, G., & Gu, Z. (2018). In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aan3682
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.